LC
SIOX

Lindbrook Capital’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

Lindbrook Capital’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-9,099
Closed -$24K – 2025
2021
Q1 		$24K Buy
9,099
+5,000
+122% +$14.1K 0.01% 693
2020
Q4 		$11K Sell
4,099
-8,901
-68% -$25.9K ﹤0.01% 881
2020
Q3 		$60K Buy
+13,000
New +$42.9K 0.02% 313

Other funds holding SIOX

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
TVWM
Tower View Wealth Management Shorewood, Wisconsin $227M AUM 41.04% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Lindbrook Capital's SIOX Position: Q2 2021 in Review

Lindbrook Capital sold out of Sio Gene Therapies Inc. Common Stock (SIOX) in Q2 2021, closing a stake of 9,099 shares — an estimated $24K sold.

Lindbrook Capital first reported a position in SIOX in Q3 2020 and held it in 3 quarters. The position peaked at $60K in Q3 2020. 54 funds tracked by Wall St. Rank hold SIOX as of Q2 2021.

  • Lindbrook Capital reported no remaining Sio Gene Therapies Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Lindbrook Capital sold 9,099 Sio Gene Therapies Inc. Common Stock shares in Q2 2021, an estimated $24K.
  • Lindbrook Capital first reported a position in Sio Gene Therapies Inc. Common Stock in Q3 2020 and held it in 3 quarters.
  • Lindbrook Capital's Sio Gene Therapies Inc. Common Stock position peaked at $60K in Q3 2020.
  • 54 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q2 2021.

Based on Lindbrook Capital's 13F filing for Q2 2021, filed 27 Jul 2021.